Nuon Therapeutics, Inc. brings together global thought leaders in both RA and MS. Both Marc Feldmann and Larry Steinman have extensive experience in the scientific investigation of autoimmune diseases, clinical development of new drugs and commercialization of new therapies. Together Professors Feldmann and Steinman are scientific co-founders, investors and shareholders of Nuon Therapeutics, Inc.
Professor Marc Feldmann, MB, BS, PhD, FRCPath, FRCP, FMedSci, FAA, FRS
- Head, Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College London
- Professor of Cellular Immunology, University of London
- Rheumatoid Arthritis expert
- Co-Inventor of anti-TNF alpha therapeutic class
- Albert Lasker Award for Clinical Medical Research, 2003
- Crafoord Prize of the Royal Swedish Academy, 2000, for anti-TNF therapy
- Nuon Co-Founder, Investor and Shareholder
Professor Larry Steinman, BA, MD
- Professor, Departments of Neurology and Neurological Sciences, Stanford University
- MD Harvard University, 1968-1973
- NIH Fellow at Harvard Medical School, 1970-1971, Senator Jacob Javits Neuroscience Investigator Award, Congress of the United States and NIH
- Multiple Sclerosis expert
- Co-Inventor of leading MS drug Tysabri
- Co-Authored with Selley of: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310: 850-5
- Nuon Co-Founder, Investor and Shareholder
Dr Michael Selley, PhD - CSO
- Previously Chief of Staff to the Australian Minister for Science and Technology
- Previously academic appointments at John Curtin School of Medical Research at the John Cutin School of Medical Research, Australian National University where he carried out research on the molecular basis of cardiovascular diseases
- Nuon Founder, Investor and Shareholder